Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Results
Phase 3
This trial looked at ipilimumab, carboplatin and paclitaxel for non small cell lung cancer (NSCLC). It was for people who had advanced NSCLC. This means that their cancer had:
spread to another part of the body
come back after treatment
Recruitment start: 1 August 2011
Recruitment end: 26 February 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Christian Ottensmeier
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Last reviewed: 27 March 2018
CRUK internal database number: 8647
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
